Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

ClinicalTrials.gov ID: NCT05388058

Public ClinicalTrials.gov record NCT05388058. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Topical Cannabidiol (CBD) for the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Randomized Placebo-Controlled Pilot Trial

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This clinical trial compares topical cannabidiol to placebo in improving chemotherapy-induced peripheral neuropathy, or painful sensations in your hands or feet due to chemotherapy. Peripheral neuropathy is a nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. It usually begins in the hands or feet and gets worse over time. Peripheral neuropathy caused by chemotherapy is called chemotherapy-induced peripheral neuropathy (CIPN). CIPN is commonly seen in patients receiving certain chemotherapy medications and is hard to treat. Medications commonly used to treat CIPN have limited benefits and may cause significant side effects. A small report showed that topical cannabidiol may help treat neuropathy in patients with diabetes. This study is being done to determine if cannabidiol cream can help improve the symptoms of CIPN.

Study identification

NCT ID: NCT05388058
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Mayo Clinic; Other
Enrollment: 40 participants

Conditions and interventions

Conditions

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 8, 2022
Primary completion: Jul 13, 2023
Completion: Jul 27, 2023
Last update posted: Jan 15, 2026

2022 – 2023

United States locations

U.S. sites: 9
U.S. states: 1
U.S. cities: 9

Facility	City	State	ZIP	Site status
Mayo Clinic Health System Albert Lea	Albert Lea	Minnesota	56007	—
Fairview Grand Itasca Clinic and Hospital	Grand Rapids	Minnesota	55744	—
Fairview Range Medical Center	Hibbing	Minnesota	55746	—
Mayo Clinic Health System Mankato	Mankato	Minnesota	56001	—
Monticello Cancer Center	Monticello	Minnesota	55362	—
Fairview Northland Medical Center	Princeton	Minnesota	55371	—
Mayo Clinic in Rochester	Rochester	Minnesota	55905	—
Sanford Thief River Falls	Thief River Falls	Minnesota	56701	—
Sanford Worthington	Worthington	Minnesota	56187	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05388058, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 15, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05388058 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →